Dr. Reddy’s Laboratories has confirmed that it is still awaiting formal market approval, known as a ‘Notice of Compliance,’ for its Semaglutide Injection from Health Canada. However, the company reached a significant milestone on April 22, 2026, by successfully securing the required Drug Identification Numbers (DINs) for the product. This development marks a key step forward in the company’s ongoing efforts to introduce the treatment to the Canadian market.
Clarification on Regulatory Status
Following recent media reports regarding the status of its Semaglutide Injection, Dr. Reddy’s Laboratories issued a formal update to clarify its current standing with Canadian health authorities. The company confirmed that while it has not yet received final approval to market the product, the project remains a high priority for its international expansion strategy.
Key Milestone Achieved
As part of the rigorous regulatory review process, the company announced that it officially received its Drug Identification Numbers (DINs) from Health Canada on April 22, 2026. The receipt of these numbers is an essential administrative requirement for the product’s eventual commercialization in the region.
Commitment to Market Entry
Dr. Reddy’s Laboratories continues to engage proactively with Health Canada to navigate the remaining steps of the regulatory pathway. The company reiterated its commitment to bringing this product to the Canadian market, noting that it will provide further updates as and when significant developments occur in alignment with its corporate disclosure obligations.
Source: BSE
